BeOne Medicines adds Phase 1 trial of BG-92505, a KEAP1 activator, in solid tumors

BeOne Medicines had one new trial registration posted this week, following last week's listing of a BON-106 study.

• A Phase 1 study (NCT07896460) will test BG-92505, an oral drug the sponsor says is a pill taken by mouth that helps turn on a protein called Kelch-like ECH-associated protein 1 (KEAP1)¹, alone or combined with other anticancer agents in patients with advanced solid tumors. The study is not yet recruiting, with an estimated start date of November 30, 2026 and estimated primary completion August 29, 2028¹, and plans to enroll 137 participants¹ across dose escalation and safety expansion parts, with monotherapy dose escalation enrolling patients with advanced, metastatic, and unresectable non-small cell lung cancer, esophageal squamous cell carcinoma, head and neck squamous cell carcinoma, or hepatocellular carcinoma who have progressed on prior standard therapy¹.
• A Phase 1a/1b study (NCT07893535) of BON-106, described by the sponsor as an experimental immunotherapy that is designed to activate immune cells that can recognize and attack tumor cells², remains listed as not yet recruiting, with an estimated enrollment of 96 participants in adults with advanced or metastatic solid tumors.